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Abstract 
 
 Heart Failure with preserved Ejection Fraction (HFpEF) is a common 
clinical syndrome that comprises 50% of Heart Failure (HF) patients. It is 
characterized by an abnormal diastolic left ventricular (LV) function, with 
impaired relaxation and increased stiffness that together contribute to the 
heart inability to fill properly. Understanding HFpEF has been difficult due to 
its heterogeneous etiology and pathophysiology, so, treatment options are still 
an enigma. Recent studies on HFpEF emphasize the importance of 
comorbidities frequently present in this syndrome, like diabetes mellitus (DM), 
obesity, hypertension and even aging, all promoting systemic inflammation 
and endothelial dysfunction.  
The recently characterize ZSF1 obese rat represents one of the most 
comprehensive animal model of HFpEF described to date. Using this model, 
we aim to better characterize HFpEF in terms of assessing inflammation, 
endothelial function and the relation between these injuries, allowing for a 
better understanding of this syndrome.  
Male rats Wistar Kyoto (WKY, n=21), ZSF1 Lean (ZSF1Ln, n=24) and 
ZSF1 Obese (ZSF1Ob, n=22) were subjected to echocardiographic 
examination at their 18th week of age and, at the end of the protocol, to 
morphometric and vascular function evaluation, as well as molecular and 
histological studies. 
 Compared to WKY and to ZSF1Ln, ZSF1Ob rats are heavier, present 
obesity with significantly more abdominal adiposity, other features of DM and 
also hypertension, three important risk factors for HFpEF. ZSF1Ob animals 
have LV hypertrophied and display diastolic dysfunction, in which an increase 
in E/E' was observed. Aortic rings, submitted to acetylcholine increasing 
concentrations, showed endothelium impairment of relaxation, suggesting 
endothelial dysfunction. ZSF1Ob animals do not presented systemic 
inflammation but had myocardial expression of inflammatory mediators, 
revealing itself to be the principal source of heart tissue inflammation. 
viii 
 
We conclude that ZSF1Ob rat represent a solid animal model for 
HFpEF research and that cardiac endothelium underlies its pathophysiology 
thus representing an interesting pathway for future pharmacologic 
interventions. 
 
 Keywords: Heart Failure with preserved Ejection Fraction; inflammation; 
endothelial dysfunction; ZSF1 obese animal model 
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Resumo 
 
Insuficiência cardíaca com fração de ejeção preservada (ICFEP) é um 
síndrome clínico bastante comum que compreende 50% dos doentes com 
insuficiência cardíaca (IC). A ICFEP é caracterizada por uma função 
ventricular comprometida, nomeadamente com alterações no relaxamento e 
aumento da rigidez, que em conjunto contribuem para a incapacidade do 
coração de encher de maneira eficiente. Compreender a ICFEP tem sido 
difícil devido à sua etiologia e patofisiologia heterogéneas, o que limita as 
opções de tratamento. Descobertas recentes dão ênfase às comorbilidades 
frequentemente presentes na ICFEP, como a diabetes mellitus, obesidade e 
hipertensão e até mesmo o envelhecimento, como sendo promotoras de 
inflamação sistémica e disfunção endotelial.   
 O rato obeso ZSF1 recentemente caracterizado representa um dos 
melhores modelos animais para a investigação na ICFEP. Utilizando este 
modelo pretendemos avaliar a inflamação e a disfunção endotelial e ainda a 
relação entre ambos, permitindo assim uma melhor compreensão deste 
síndrome.    
 Ratos machos com nove semanas de idade Wistar Kyoto (WKY, 
n=21), ZSF1 magros (ZSF1Ln, n=24) e ZSF1 obesos (ZSF1Ob, n=22) foram 
submetidos a avaliações ecocardiográficas às 18 semanas de idade, e no fim 
do protocolo, a avaliações morfométricas e de função vascular, assim como a 
estudos moleculares e histológicos. 
 Comparando com os grupos WKY e ZSF1Ln, os ratos ZSF1Ob têm 
mais peso corporal, são obesos e têm mais gordura abdominal, possuem 
características da diabetes mellitus e hipertensão, três fatores de risco 
relacionados com a ICFEP. Os ratos ZSF1Ob têm hipertrofia ventricular 
esquerda e apresentam disfunção diastólica, com um aumento da razão E/E’. 
Anéis aórticos submetidos a concentrações crescentes de acetilcolina 
mostraram um comprometimento no relaxamento do endotélio, sugerindo um 
estado de disfunção endotelial. Células endoteliais cardíacas de animais 
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ZSF1Ob mostraram expressão de factores inflamatórios importantes, 
revelando ser a principal fonte de inflamação no tecido cardíaco. 
Conclui-se que os ratos ZSF1Ob representam um bom modelo animal 
para investigação na ICFEP e que o endotélio cardíaco é alvo interessante 
para futuras intervenções farmacológicas.  
 
Palavras-chave: Insuficiência cardíaca com fração de ejeção preservada; 
inflamação; disfunção endotelial; modelo animal ZSF1 obeso 
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“There are many hypotheses in science which are wrong. That’s perfectly all right: it’s 
the aperture to finding out what’s right. Science is a self-correcting process.” 
Carl Sagan 
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1. Heart Failure 
 
 
1.1.  Definition 
The first description of Heart Failure (HF) remotes to ancient Egypt 
times. Its definition remains controversial partly because of his complicated 
etiology and also because of the variability of the clinical symptoms and signs. 
HF is the end-result of many cardiovascular diseases and a clinical syndrome 
characterized by functional and structural irregularities in human heart that 
compromise its capacity to eject sufficient blood to fulfill all body’s metabolic 
needs or only at the expense of increased ventricular filling pressures [1-3]. 
 
1.2.  Epidemiology 
The epidemiology of HF had a remarkable revolution in the last 
decades. Worldwide the total number of estimated HF patients is around 26 
million. Results from the Framingham Heart Study suggest that in developed 
countries, at some point of their life, one in five persons will develop HF. In 
Europe, according to the Rotterdam study, the 5-year mortality risk is around 
41% [4, 5]. 
The number of patients with HF will grow to epidemic proportions 
considering the expected increase of population ageing, the sedentary 
lifestyle expected for the next years and the estimated increase of HF 
comorbidities like diabetes mellitus (DM) and obesity, thus representing a 
major public health problem [4-6].  
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1.3.  Symptoms and signs 
According to European Society of Cardiology, symptoms of HF include 
dyspnea (difficulty in breathing), fatigue and exercise intolerance [7, 8]. 
Signs of HF include leg, ankles and feet swelling, jugular distension, 
pulmonary rales, peripheral edema and some radiographic manifestations like 
pulmonary vascular redistribution, interstitial edema and pleural effusions [8]. 
 
1.4. Classification and Pathophysiology  
 
According to the European Society of Cardiology and to the American 
College of Cardiology Foundation/American Heart Association HF patients 
can be divided in two clinically distinct syndromes: HF with reduced Ejection 
Fraction (HFrEF) or systolic HF and HF with preserved Ejection Fraction 
(HFpEF) also known as diastolic HF [9]. 
 
HFrEF is correlated with ischemic injury, dilated and other genetic 
cardiomyopathies, whereas HFpEF is associated with chronic inflammation 
and the co-existence of other comorbidities which represent important 
cardiovascular risk factors. Comparing both types, HFpEF patients have fewer 
hospitalizations but higher mortality rate than HFrEF. Contrarily to HFrEF, 
there is not any effective medical treatment for HFpEF as a result of the 
diversity and complexity of pathophysiology of this condition [7, 10]. The 
heterogeneous etiologies and the challenging diagnostic make HFpEF an 
interesting topic for research. Current treatment strategies focus on control of 
volume status and comorbidities, but future research aimed at individualized 
therapies holds promise to improve outcomes in this increasingly prevalent 
form of cardiac failure. 
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1.4.1. Heart Failure with Preserved Ejection Fraction 
HFpEF constitutes almost 50% of all HF patients and its prevalence is 
increasing almost 1% per year [11]. HFpEF is more common in older women 
(61-76% of patients) with high prevalence of hypertension, DM, ischemic 
heart disease, coronary artery disease, atrial fibrillation and lifestyle related 
risk factors like smoking and obesity [1, 12-16].  
HFpEF is associated with left ventricle (LV) diastolic dysfunction and 
involves complex interactions between multiple factors. In the diastolic phase, 
the ventricle is unable to fill with sufficient blood maintaining adequate low 
pressures resulting from myocardium stiffness or impaired relaxation. The 
increased filling pressure (stiffness) induces wall thickness and an adjustment 
in ventricular size and volume (Figure 1) [8, 17-20]. Besides the diastolic 
dysfunction, some other mechanisms seem to be related with HFpEF 
pathophysiology, such as inflammation, chronic volume overload, venous 
constriction, irregular ventricular-vascular coupling, as well as cardiac 
autonomic impairment and chronotropic incompetence. In this condition the 
heart rate response to stress is abnormal what could lead to pulmonary 
arterial hypertension and endothelial dysfunction [15].  
 
Figure 1. Schematic representation of the evolution of a normal heart into HFpEF, 
involving the exposure to several risk factors. Risk factors are responsible for 
myocardium alterations that include readjustment in ventricular size and volume, 
myocardium stiffness and wall thickness, therefore contributing to the development of 
HFpEF. Figure was produced using Servier Medical Art.  
24 
 
The challenging diagnosis of HFpEF is assessed after clinical 
evaluation, Doppler echocardiography or invasive hemodynamic assessment 
and confirmed whenever the following conditions are observed [7, 21, 22]:  
 Signs and symptoms of HF;  
 Diastolic dysfunction;  
 Normal or lightly anomalous systolic function. 
 
Despite all advances in medicine, HFpEF continues to have a high rate 
of hospitalizations, subsequent readmission on hospital, a considerable 
mortality rate (10-30%) and will grow to epidemic proportions making it a 
major public health problem [1, 12, 23].  
 
 
1.5.  Comorbidities in HFpEF  
Non-cardiac comorbidities are highly prevalent in HFpEF and have an 
important role in the pathogenesis of this syndrome [11]. Several risk factors 
are involved, although only one is enough to cause HFpEF. Patients with 
HFpEF usually have multiple comorbidities that could cause or be contributors 
to this phenotype [15].  
Female gender is also an important risk factor being associated with 
more concentric remodeling, lower LV diastolic volumes and as well as 
systolic and diastolic LV stiffness. Woman have a probability two times higher 
to develop HFpEF [11, 24].   
Anemia is present in 50-70% of HFpEF patients and it is closely related 
with renal disease and it is characterized by iron deficiency and insufficient 
erythropoietin production generated by systemic inflammation. Chronic renal 
failure and HFpEF often co-exist and share common risk factors. Indeed, 
renal failure is present in 30-40% of patients and it is a predictor of mortality. 
Chronic obstructive pulmonary disease (COPD) also contributes to HFpEF 
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mortality and the adverse cardiovascular effects include reduction of cardiac 
output, less stroke volume and also impaired LV filling [11, 25].   
Hypertension is the most predominant risk factor, being present in 60-
88% of HFpEF patients. In hypertensive patients, the risk of developing 
HFpEF is 2 times higher in men and 3 times higher in women comparing with 
the normotensive patients. High blood pressure is capable of increase arterial 
stiffness, which compromises LV relaxation. Additionally, these patients 
frequently display obesity, microalbuminuria and impairment of insulin 
signaling and rapidly develop myocardial fibrosis and LV hypertrophy [11].  
Obesity, which has reached epidemic proportions partly because of the 
increase of energy intake and a sedentary life style, impairs cardiac structure 
and function that doubles the risk of having HFpEF. It is present in 32-46% of 
patients and it is an independent risk factor for cardiovascular morbidity and 
mortality. Along with adipose tissue expansion, pro-inflammatory cytokines 
and adipokines, like leptin and resistin, are released. Arterial resistance 
increases and contributes to LV hypertrophy and high diastolic pressures. 
Myocardial relaxation is compromised due to changes in cardiomyocyte 
calcium handling, along with lipotoxicity and mitochondrial dysfunction. All 
these alterations induce LV concentric remodeling, LV increase of mass e 
volume and arterial stiffness [11, 12].  
Diabetes mellitus (DM) is a recognized comorbidity affecting 30-45% of 
HFpEF patients, especially females. The Framingham Heart Study first 
showed that diabetic patients can develop diastolic LV thickness with stiffer 
cardiomyocytes and subsequent studies from our group further confirmed this 
evidence [26]. This is a result of hyperglycemia effects that causes interstitial 
and perivascular fibrosis, increase collagen deposition and reduction of 
degrading matrix metalloproteinases [11, 12, 15]. Additionally, high levels of 
glucose promote the generation of advanced glycation end-products (AGEs) 
in myocardium, which are molecules formed in the reducing sugars’ reaction 
that can form covalent bonds with proteins, namely collagen fibers cross-
linking, stiffening the myocardium. Moreover, AGEs can bind their receptors, 
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RAGEs, increasing collagen production thus, decreasing arteries distensibility 
and increasing LV stiffness [11, 27, 28]. 
All the previous comorbidities are associated with several pathological 
changes in the cardiovascular system that strongly contribute to HFpEF. 
Besides diastolic LV dysfunction, myocardial and systemic inflammation, 
oxidative stress and endothelial dysfunction represent important contributors 
to the pathophysiological mechanisms of HFpEF syndrome [11, 12]. The 
endothelium, located between the circulating blood and the vessel wall or the 
myocardium, occupies a strategic anatomic position and is undoubtedly 
involved in the abnormalities that occur in HFpEF [29-34]. 
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2. HFpEF and the endothelium  
 
2.1.  The endothelium 
Endothelium is an active organ formed by a monolayer of endothelial 
cells that separate the vascular wall or the myocardium from the circulation. It 
acts as a functional and structural barrier capable of sensing hormonal and 
mechanical stimuli. The endothelium plays an important role in cardiovascular 
homeostasis modulating vascular tone by balancing the production of 
vasodilators and vasoconstrictors agents (Table 1). In addition, this layer also 
regulates solute transport, prevent leucocyte and platelet adhesion and 
aggregation, modulates blood flow and mediates inflammatory and reparative 
response to injury [32, 35-37]. Cardiac endothelium integrates endothelial 
cells from endocardium, from the coronary microvasculature and also of the 
intramyocardial capillaries. The anatomical position of endothelial cells next to 
cardiomyocytes enables a bidirectional communication between those cells 
[38]. Several studies have shown that endothelium have a crucial role in 
several diseases, including HFpEF [35, 39].  
Table 1. Vasoactive and inflammatory substances released by endothelium [36, 40]. 
Action Substance 
Vasodilation 
 
Nitric Oxide (NO) 
Prostacyclin 
C-Type natriuretic peptide 
Vasoconstriction 
 
Endothelin-1 (ET-1) 
Angiotensin II (Ang II) 
Thromboxane A2 
Reactive Oxygen Species (ROS) 
Inflammation 
 
Nitric Oxide (NO) 
E and P-selectin 
Nuclear Factor kβ (NF- kβ) 
ICAM1 
VCAM1 
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Nitric oxide (NO) is the most important and the most characterized 
substance produced by the endothelium. This gas with a short life (about 6-30 
seconds) is generated from L-arginine amino acid by endothelial NO synthase 
(eNOS) which is continuously produced and release by endothelial cells 
through physical and hormonal stimuli [41]. Shear stress caused by blood 
flowing on the vessel wall is the most important physical stimuli for NO 
production. Chemical stimuli include acetylcholine, bradykinin and serotonin 
[41, 42]. In the healthy endothelium, when NO is released, binds to smooth 
muscle promoting the activation of soluble Guanylate Cyclase (sGC) and the 
production of cyclic Guanosine Monophosphate (cGMP) which opens calcium 
dependent potassium channels promoting blood vessel relaxation and 
vasodilation (Figure 2). Normally, NO is important to maintain the vascular 
wall in a quiescent state inhibiting inflammation, cell proliferation and 
thrombosis being the vasodilation prevalent (Table 2) [41-45].  
 
Figure 2. Synthesis of Nitric Oxide. In endothelial cells NO production is stimulated 
by several stimulus and inhibited by others. NO acts in smooth muscle cells in order 
to promote vasodilation and the decrease of cytokine synthesis, the monocyte 
adhesion and platelet aggregation, as well as the decrease of adhesion molecules.  
NO: Nitric Oxide; eNOS: endothelial Nitric Oxide Synthase; GTP: Guanosine 
Triphosphate; sGC: soluble Guanylate Cyclase; cGMP: cyclic Guanosine 
Monophosphate. Figure was produced using Servier Medical Art. Adapted from [41, 
42]. 
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Table 2. Role of Nitric Oxide. Adapted from [41]. 
Role Action 
Vasomotor action 
 
Endothelium vasodilation 
Decreases vasoconstriction in smooth muscle cells 
Regulation of systemic and coronary tone by acting on basal 
arterioles 
Inflammation 
 
Decreases endothelial permeability 
Decreases expression of E-selectin 
Reduction of leucocyte adherence to the endothelium 
Decreases production of macrophages cytokines 
Down-regulate platelet aggregation and adherence 
Antioxidant 
 
In vivo and in vitro free radical scavenger 
NO donors duplicate plasma anti-oxidant capacity 
 
 
 
2.2. Endothelial dysfunction  
As a consequence of HFpEF risk factors, endothelium loses his 
integrity and the homeostatic balance is disrupted, culminating in endothelial 
dysfunction. Endothelium acquires a pro-inflammatory and pro-thrombotic 
state with vasoconstriction that includes detachment and release of 
endothelial cells into the circulation [35, 39, 44, 46]. Endothelial dysfunction is 
associated with the beginning and the progression of HFpEF [32, 34, 40, 47]. 
The principal feature of endothelial dysfunction is the impairment of NO 
bioavailability. In this condition, reduced production of NO can result from 
diverse contributing factors, such as decreased production of eNOS, lack of 
eNOS substrates or due NO degradation by ROS (Figure 3). ROS are 
chemical oxygen species and cellular metabolism’s products that are highly 
reactive causing oxidative stress [37, 38]. ROS form peroxinitrites that impair 
the NO-induced vasodilation, essential to vascular homeostasis and 
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endothelial function. Reduced NO release by endothelium affects ventricular 
relaxation, particularly in the hypertrophied myocardium. Conventional 
antioxidant therapies have intended to correct the imbalance between NO and 
ROS, but sadly have not been totally successful yet [36, 40, 48-50].  
 The link between endothelial dysfunction and HFpEF pathophysiology 
is currently established [11, 32, 33, 36, 41]. However the precise mechanisms 
remain obscure. Understanding endothelial dysfunction mechanisms will be 
an important key to understand the pathophysiology of HFpEF. 
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Figure 3. Schematic representation of the differences between a healthy (A) and 
dysfunctional endothelium (B). In a healthy endothelium, endothelial cells are intact 
and produce a normal concentration of nitric oxide (NO) by endothelial nitric oxide 
synthase (eNOS). In a dysfunctional endothelium, endothelial cells are damaged and 
produce a reduced concentration of NO due reaction with reactive oxygen species 
(ROS) and a decreased eNOS activity. It becomes an inflammatory local and 
leucocytes and platelets migrate to this injury site. Figure was produced using 
Servier Medical Art.  
B – Dysfunctional endothelium 
A – Normal endothelium 
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2.3. Mechanisms of endothelial dysfunction in HFpEF: the role 
of comorbidities 
Newer insights suggest that endothelial dysfunction is more than a 
state of systemic vasoconstriction and that has a crucial role in HFpEF 
pathogenesis. In 2013 Paulus et al. suggested that endothelial dysfunction 
plays a central role in HFpEF progression. These new paradigm of HFpEF 
suggests that comorbidities are responsible for the pro-inflammatory state 
seen, causing coronary microvascular endothelial inflammation [51].     
 Hypertension, obesity and DM induce a systemic inflammatory state 
with the release of pro-inflammatory cytokines such as tumor necrosis factor α 
(TNFα), interleukin-1 (Il1), Il-6 and Il-8. Increased circulating levels of these 
cytokines are found in HFpEF patients [11, 13].  The adhesion molecules, 
vascular cell adhesion molecule 1 (VCAM1), intercellular adhesion molecule 1 
(ICAM1) and E-selectin, which in normal conditions are expressed in small 
amounts in the surface of endothelial cells, are upregulated [13, 52]. 
Endothelial inflammation originates the production of ROS that leads to 
peroxynitrites (ONOO-) formation and a decrease in NO bioavailability. In 
response, cardiomyocyte production of soluble guanylate cyclase (sGC) is 
reduced, which contributes to a decrease in cGMP and protein kinase G 
(PKG) concentration. In HFpEF lower PKG levels are associated with 
cardiomyocyte hypertrophy and stiffness, and with high resting tension 
(Fpassive). This high resting tension is due to the hypophosphorylation of the 
N2B segment of the giant cardiomyocyte cytoskeletal protein titin [11, 38, 51, 
53]. Microvascular endothelial inflammation also stimulates fibroblasts 
differentiation in myofibroblasts resulting in myocardial fibrosis with collagen 
type 1 deposition and collagen cross-linking, which are contributors to 
myocardial stiffening [54]. These changes induce diastolic LV dysfunction, the 
major characteristic of HFpEF (Figure 4) [11, 38, 51]. 
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Figure 4. Schematic representation of the mechanisms induced by comorbidities that 
result in myocardial dysfunction and remodeling in HFpEF. Comorbidities generate a 
pro-inflammatory state with consequent release of Interleukin (Il) 1, Il-6, Il-8 and 
Tumor Necrosis Factor α (TNFα). Endothelium produces reactive oxygen species 
(ROS) that react with nitric oxide (NO) to produce peroxynitrites (ONOO-) and at the 
same time reduce NO bioavailability. In cardiomyocytes there is a reduction in 
soluble guanylate cyclase (sGC), which in turn decreases cyclic guanosine 
monophosphate (cGMP) concentration and protein kinase G (PKG) production. Titin 
hypophosphorylation induces an increase in passive force leading to cardiomyocyte 
hypertrophy. Endothelial cells increase the expression of adhesion molecules 
(ICAM1, VCAM1 and E-selectin) influencing the migration of monocytes that release 
transforming growth factor (TGFβ). This last induces the collagen production and 
deposition in interstitial space which is turn causes cardiomyocyte stiffness. Figure 
was produced using Servier Medical Art. Adapted from [11, 51]. 
 
 
Nevertheless, the exact role that comorbidities have on structural and 
functional remodeling in HFpEF is not entirely well known. The new paradigm 
of HFpEF could be a new therapeutic target and the development of 
experimental HFpEF models might be beneficial and helpful, in order to 
understand and possibly to cure this pathology [11].  
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3. Animal models in HFpEF research 
 
Understanding the pathophysiology of HFpEF has been restricted by 
the limited access to human myocardial biopsied due to obvious ethical 
constrictions. In addition, the lack of a proper animal model mimicking the 
human pathology has partly limited HFpEF research. Indeed, animal models 
can be very useful to clarify subcellular mechanisms under conditions where 
the comorbidities and other confounding factors can be precisely controlled 
[55, 56].   
There are several models used for HFpEF research, nevertheless, until 
recently, none had fulfilled all the features present in the human disease. 
Recently, we have characterized a rat model that meets the criteria of HFpEF, 
the obese ZSF1 [57]. 
 
3.1. The obese ZSF1 as an animal model of HFpEF 
ZSF1 rats were generated by crossing non-hypertensive lean female 
Zucker Diabetic Fatty rats (ZDF, +/fa) with lean spontaneously hypertensive 
HF prone male rats (SHHF/Mcc, +/facp) that share a common genetic 
background with Wistar Kyoto (WKY) rats and derive from spontaneously 
multifactorial hypertensive rats  [58-63]. Both lean and obese ZSF1 animals, 
inherit a hypertensive gene from the spontaneously hypertensive rat strain 
and show elevated blood pressure [59]. 
ZSF1 rats have myocardial hypertrophy induced by hypertension, more 
notorious in obese than in lean rats. The ZSF1 obese rats present 
considerable diastolic abnormalities such as increased left atrial area, 
prolonged time constant of isovolumetric relaxation, elevated arterial 
elastance and end-diastolic pressure as well as an upwards shift of end-
diastolic pressure-volume relation, thus highlighting a worse ventricular-
vascular coupling. Systolic function remained preserved in lean and obese 
ZSF1 rats [57]. 
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In terms of metabolic disturbances, ZSF1 obese animals developed 
obesity, abdominal adiposity, insulin resistance, oral glucose intolerance, 
hyperglycemia and glycosuria, consistent with type II DM phenotype [64] and 
thus represent a good animal model of metabolic syndrome. Moreover, 
compared to hypertensive ZSF1 lean, which represent a model of isolated 
ventricular overload, the ZSF1 obese will allow clarifying if imposing metabolic 
comorbidities on top of overload is per se capable of induced HFpEF. 
Recently, a full description of a rat model that meets the criteria of diastolic HF 
was described, the ZSF1 obese [57]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part 2  
Aims 
 
 
 
 
 
 
 
 
 
 
 
 
 
“The scientist is not a person who gives the right answers; he's one who asks the 
right questions.” 
Claude Lévi-Strauss 
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Considering the concepts reviewed before, the aim of the present study 
was to clarify the pathophysiology of HFpEF by investigating the contribution 
of endothelial dysfunction and inflammation for the development of this 
syndrome.  
 
In order to achieve the aim of the project we pretend to: 
 
 Characterize an animal model of HFpEF including metabolic, 
morphometric as well as cardiac structural and functional changes; 
 Evaluate endothelial dysfunction in the previous model; 
 Correlate endothelial dysfunction with cardiac function parameters 
to investigate potential therapeutic targets.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part 3  
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Those who are quite satisfied sit still and do nothing; those who are not quite 
satisfied are the sole benefactors of the world.” 
Walter Savage Landor 
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1. Experimental animal model 
 
This study was made according to the Guide for the Care and Use of 
Laboratory Animals published by the NIH (NIH Publication no. 85–23, revised 
2011) and was approved by the ethics committee of the Faculty of Medicine of 
Porto and by Direção-Geral de Alimentação e Veterinária (DGAV) from 
Portugal. The Faculty of Medicine of Porto is a governmental institution, 
granted approval by the Portuguese government to perform animal 
experiments. 
Nine-weeks old male rats Wistar Kyoto (WKY, n=21), ZSF1 Lean 
(ZSF1Ln, n=24) and ZSF1 Obese (ZSF1Ob, n=22) were obtained from 
Charles River (Barcelona, Spain) and had unlimited access to food (LabDiet® 
5008, International Product Supplies Ltd., UK) and water. Animals were 
housed in groups of 2 animals per cage in a ventilated cages system (IVC) in 
a controlled environment with a 12-h-light/-dark cycle at 22ºC room 
temperature. The room had a relative humidity of 30–70% and an air 
exchange rate of 40–50 air changes/hour.  
 
In the end of the experiment, at their 20th week of age, anesthetized 
animals (8% for induction and 2.5-3% for maintenance) were euthanized by 
exsanguination and blood and tissue were collected. Organs were weighed, 
RV and LV were weighed after dissection, and tibia length (TL) was 
measured. Fresh samples of LV were used in flow cytometry and the rest of 
the samples were snap-frozen in liquid nitrogen and stored at -80ºC for 
molecular studies (RNA extraction, western blot) or fixed in 10% buffered 
formalin for histological procedures and also for immunohistochemistry 
analysis. Weights were normalized to TL due to the large body weight 
differences between groups. 
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2. Echocardiography 
 
All animals were subjected to an echocardiography evaluation at their 
18th week.   Animals were anaesthetized by inhalation of sevoflurane (8% for 
induction and 1-2.5% for maintenance), orotracheally intubated and 
mechanically ventilated (150 min−1, 100% O2, 14–16cmH2O inspiratory 
pressure, with tidal volume adjusted to animal weight, and 4cmH2O end-
expiratory pressure) (TOPO Small Animal Ventilator, Kent Scientific Inc., 
USA). Rats were placed in a left-lateral decubitus position on a heating pad, 
the ECG was monitored and their temperature was kept at 38ºC. The skin of 
all animals was shaved, the echocardiography gel was applied and a linear 
15MHz probe (Sequoia 15L8W) was gently positioned on the thorax. Systolic 
and diastolic wall thickness and cavity dimensions were recorded, in M-mode 
and 2D echocardiography, at the level immediately above the papillary 
muscles in the parasternal short axis view.  
From these measurements end diastolic and end systolic volumes, 
(EDV and ESV, respectively), fractional shortening (FS), ejection fraction (EF) 
of the LV, stroke volume (SV) and cardiac output (CO) were derived. The 
following Doppler and tissue Doppler measurements were taken using the 
apical four-chamber early diastolic filling peak velocity (E wave), late diastolic 
peak velocity (A wave), E/A ratio, early peak diastolic filling velocity (E’), late 
peak diastolic filling velocity (A’) and mitral annular systolic velocity (S’).  
The myocardial performance or TEI index was retrieved from the mitral 
flow pattern and calculated by the formula = (IVCT + IVRT)/ET, were IVCT is 
the isovolumic contraction time, IVRT corresponds to the isovolumic 
relaxation time and ET to ejection time. Data was indexed for body surface 
area as described previously [65] and three representative cycles were 
measured per rat and their average was calculated. 
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3. ELISA assay 
 Blood samples collected from subclavian vein after echocardiographic 
evaluation were placed in tubes with EDTA (C10H16N2O8, pH 6.0). Samples 
were centrifuged at 5000 rpm for 15 minutes at 4°C and plasma was then 
separated and utilized for quantitative enzyme immunoassays (ELISA).    
  Levels of leptin (SK00050-08, Adipo bioscience, USA), Fatty Acid 
Binding Protein 4 (FABP4, SK00030-03, Adipo bioscience, USA) Angiotensin 
1-7 (Ang 1-7, E02A0225, BlueGene Biotech, China), Il6 (R6000B, R&D 
Systems, UK) and TNFα (ER3TNFA, Thermo Scientifics, USA) were 
measured according to the manufacturer’s instructions.  Results were 
analyzed using an ELISA plate reader (UVM-340, ASYS Hitech GmbH, 
Austria) and a calibration curve was constructed by plotting the absorbance 
values at 450nm (with specific correction, according to manufacturer’s 
protocol) and concentrations of unknown samples were determined. 
 
4. Array protein expression profile  
The expression of some inflammation related-proteins was performed 
using plasma samples and a Rat Adipokine Array Kit (ARY016, R&D systems, 
UK). 
Nitrocellulose membranes were blocked for 1 hour with an array buffer 
and then a cocktail of biotinylated detection antibodies was added and 
incubated overnight at 4ºC. The membranes were washed several times in 
order to remove all the unbound material. Streptavidin-HRP, an enzyme used 
for the detection of the substrate was applied, incubated for 30 minutes and 
washed. Finally Chemi Reagent Mix was added and the signal produced was 
measured in a chemiluminescence detection system (ChemiDoc™ MP, Bio-
Rad, USA). 
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5. Histology, cardiomyocyte and aorta dimensions   
LV and descending aortic samples were fixed in 4% paraformaldehyde, 
dehydrated with gradual ethanol, cleared with xylene and were included in 
paraffin blocks. Serial sections with 4 µm of thickness were cut using a 
microtome (RM2125RTS, Leica, Germany) and mounted on slides. Next the 
slides were dewaxed in xylene, hydrated through a series of decreasing 
concentration of alcohol solutions and stained for haematoxylin-eosin. Slides 
were subsequently submitted to a new series of decreasing concentration of 
alcohol solutions and xylene and finally mounted with Entellan (Merck, 
Germany). 
Cardiomyocyte cross-sectional area, descending aortic diameter and 
thickness were determined observing slides at light microscopy (Dialux 20, 
Leitz, Germany) and using image acquisition software (cell B, Olympus, USA).   
 
 
6. AGEs immunohistochemistry  
Immunohistochemistry was performed to determine AGEs expression 
in myocardium and in 25-50, 50-100, and >100 vessels caliber. Four- µm LV 
apex sections were sliced, placed and subjected to deparaffinization and 
rehydration.  
A heat solution of sodium citrate buffer 10mM (C6H5Na3O7.2H2O, pH 
6.0) was added for 30 minutes into the slides to induce antigen retrieval. All 
sections were encircled with a hydrophobic pen (Immunopen, Immunologic, 
Netherlands) to prevent splitting leakage and the endogenous peroxidase 
activity was blocked using 100µL/section of a 3% hydrogen peroxide solution 
(Sigma Aldrich, USA) and incubated at room temperature for 10 minutes. All 
slides were washed with distillated H2O (dH2O) and with Tris-Buffered Saline-
Tween (TBST; 100 mM Tris, 1.5 mM NaCl, pH 8.0 and 0.1% Tween-20) for 5 
minutes with agitation. Blockage of non-specific binding was prepared with 
5% normal goat serum (NGS, ab7481, abcam, Cambridge, UK) in TBST, 
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added 100 µL for section and incubated at 1 hour at room temperature. Next 
all slides were washed 3 times for 5 minutes with TBST with agitation. 
Blockage of endogenous avidin-biotin expression was preform at room 
temperature using an endogenous avidin + biotin blocking system (ab3387, 
abcam, Cambridge, UK) according to manufacturer’s instructions (1 drop and 
15 minutes of incubation). The primary antibody (Anti-AGE primary antibody, 
ab23722, abcam, UK) in a 1/500 dilution was incubated at 4ºC overnight. 
After incubation slides were washed 3 times for 5 minutes with TBST and with 
agitation and were incubated with the secondary antibody (goat anti-rabbit 
IgG, ab6720, abcam, UK) in a 1/250 dilution at room temperature for 2 hours. 
Slides were next washed with agitation 3 times for 5 minutes with TBST. All 
slides were incubated with 3.3-diaminobenzidine (DAB, ab94665, abcam, UK) 
at room temperature until brown color was observed. Then slides were 
washed with dH2O and counterstained with Gill haematoxylin (Merck, 
Germany) for 3 minutes. Finally all slides were submitted to decreasing 
concentration of alcohol solutions, xylene and mounted with Entellan (Merck, 
Germany).  
Negative control was made with the omission of the primary antibody. 
The slides were observed and photographed with a microscope (Dialux 20, 
Leitz, Germany) and AGE’s quantification was made using Image Pro Plus 6 
software (MediaCybernetics, USA). 
 
 
7. Western Blotting 
LV samples were homogenized on ice in 1 ml RIPA lysis buffer (150 
mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 
and 50 mM Tris, pH 8.0) containing the following protease inhibitors: 
phenylmethylsulfonyl fluoride (1mM), aprotonin (10g.ml−1), leupeptin 
(10 μg.ml−1) and pepstatin (10 μg.ml−1), all from Sigma Chemicals (USA). 
Samples were then centrifuged at 11000 rpm for 20 minutes at 4°C. The 
supernatants were collected and total protein concentration was determined. 
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Samples containing 20 μg of protein were loaded on a 6% SDS 
Polyacrylamide gel (SDS-PAGE), run and electroblotted into polyvinylidene 
difluoride membrane. Pre-stained molecular weight marker proteins were 
used as standards for the SDS-PAGE. Ponceau staining was performed to 
verify the quality of the transfer and to ensure equal protein loading. Blots 
were blocked in 5% non-fat skimmed milk in PBS for 1 hour, treated overnight 
with antibody against the different proteins (eNOS, 9572, Cell Signaling 
Technology, USA; β-actin, 4967, Cell Signaling Technology, USA; p-eNOS, 
9571, Cell Signaling Technology, USA) followed by incubation with alkaline 
phosphatase secondary antibodies for 1 hour. Immunoblots were developed 
with an ECFTM Western blotting detection system (GE Healthcare, UK). 
Protein content was determined using a Bio-Rad protein assay kit.  
 
 
8. Cardiac endothelial cells isolation  
A LV sample was cut and transferred into a gentleMACS C tube 
(Miltenyl Biotec, Germany) containing HBSS (CaCl2, MgCl2, 
Lifetechnologies,USA) with collagenase II (Worthington, USA) and DNase I 
(Applichem, USA). The C tube was connected to the gentleMACS dissociator 
(Miltenyl Biotec, Germany) and the sample was incubated for 30 minutes at 
37ºC with agitation every 5 minutes in order to resuspend the settled tissue 
fragments. Next the C tube was runned out again in the gentleMACS 
dissociator. In the end, the solution was passed into a 70µm cell strainer 
(Corning, USA), washed with cold HBSS and the cell suspension suffered a 
spin down at 1500 rpm for 10 minutes at 4ºC. Cold HBSS was immediately 
added and the cell suspension suffered a new spin down at 1500 rpm for 10 
minutes at 4ºC. Next cells were washed with FACS medium (eBioscience, 
USA), suffered another spin down at 1500 rpm for 10 minutes at 4ºC and 
resuspended in HBSS (1ml/heart). 
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9. Flow cytometry and sorting  
Cardiac endothelial cells were resuspended in ice-cold FACS medium 
(eBioscience, USA) and added into a 96 well plate (105-106 cells/well) in a 
way that surrounding each well stays an empty one. FACS medium was 
added, the plate was washed by centrifugation for 5 minutes for 2000 rpm and 
supernatant was discarded. CD90 Pacific blue (Biolegend, USA), PE anti-rat 
CD54 (Biolegend, USA), CD44 Purified (BD Biosciences, USA) and CD106-
Pe (BD Biosciences, USA) antibodies were added in a dilution in FACS 
medium to a maximum volume of 25-50 µl and incubated on ice for 20 
minutes protected from light. FACS medium was added and the plate was 
washed by centrifugation for 5 minutes for 2000 rpm. The supernatant was 
discarded. In order to loose cells, the plate suffered a shacking in a vortex set 
at medium speed. Cells were transferred into FACS tubes (eBioscience, USA) 
with the remaining volume up to a total of 400µL. The tubes were protected 
from light and read it in FACS (eBioscience, USA) and cells suffer cell sorting. 
 
10. RNA extraction and reverse transcription 
LV sample from each animal was cut and putted in tubes with 500 µl 
Tripure each (Roche, USA). In a fume hood each tube was homogenized and 
then incubated in room temperature for 5 minutes. Chloroform was added on 
all tubes, which suffered a rapid vortex, and then were incubated for 10 
minutes in room temperature. Next all tubes were centrifuged at 15000 rpm at 
4ºC for 15 minutes and the resulting aqueous phase was collected to a new 
tube with isopropanol. The tubes suffered a rapid vortex and were incubated 
at room temperature for 10 minutes. In the end all were centrifuged at 15000 
rpm at 4ºC for 10 minutes and the supernatant was discarded. The resulting 
pellet was washed with 70% ethanol and a rapid vortex was made. The tubes 
were centrifuged for 5 minutes at 15000 rpm at 4ºC, the supernatant was 
discarded again and the tubes were left opened and turned down in order to 
completely dry the pellet. RNase free water (Qiagen, Netherlands) was added 
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and for 30 minutes all tubes were left on ice to dissolve the pellet. In the end 
all tubes suffered a vortex and reverse transcription protocol. 
RNA concentration from all samples was adjusted in order to perform a 
1µg of total RNA in a 20 µL volume.  Random Primers in a 1/5 concentration 
were added to the samples and were incubated for 20 minutes at room 
temperature and 3 minutes on ice. 
A mix containing 5X buffer (Invitrogen, USA), dNTPs (Invitrogen, USA), 
DTT (Invitrogen, USA), RNase free water (Qiagen, Netherlands), RNasin 
(Promega, USA), MgCl2 (Thermo Scientific, USA) and SuperScript II 
(Invitrogen, USA), was made and distributed to each sample. Two negative 
controls were also prepared: no template control (NTC) in which samples 
were substituted by RNase free water to verify if reagents were contaminated; 
and RT- in which SuperScript II is substituted by RNase free water to verify if 
samples are contaminated with genomic DNA. The reaction mixtures were 
incubated in Thermocycler (Biometra, Germany) in 25ºC for 10 minutes, 42ºC 
for 50 minutes and 70ºC for 15 minutes. 
 
 
 
11. Real time - PCR  
Real-time PCR was performed StepOnePlus™ Real-Time PCR System 
(Applied Biosystems, USA) with myocardium cells, using 96-well 0.1 ml PCR 
plates (Applied Biosystems, USA) and carried out with SYBR Green 2X 
Master Mix (Qiagen, Netherlands). The primers were obtained from Thermo 
Scientific (Germany). Amplification reactions were performed in duplicate and 
the amount of RNA in the reactions was normalized with an internal control, 
the constitutively expressed gene Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as its mRNA levels were similar between groups. 
Gene expression was quantified using the comparative Ct method (2-ΔCt), 
where ΔCt = Cttarget gene – CtGAPDH.  
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12. Vascular function 
Aortic rings with about 1.5 mm were isolated from ascending aorta 
samples and assembled between metal pins in an organ bath system 
(770MO, Danish Myo Technology). After stabilization, a curve of passive 
tension-length by progressive mono-axial stretching was obtained of the 
vascular rings at intervals of 20%, since the diameter with no tension - without 
stretching (L0) until 200% of L0. The strain (Ɛ) was defined as the proportional 
increase of length in relation to L0. The passive tension curve was 
mathematically modulated by an exponential function, in which β is a vascular 
stiffness index.  In every step an active tension curve with KCl stimulation was 
obtained. After passive tension adjustment of the vascular ring, and 
considering a resting transmural pressure of 100 mmHg, vascular reactivity 
was evaluated thought an dose-response curve to phenylephrine (Phe; 10-9 to 
10-5, in logarithmic 0.5 intervals) and the endothelial function thought an dose-
response curve to acetylcholine (Ach; 10-9 to 10-4, in logarithmic 0.5 intervals), 
being the relaxation evaluated according to the percentage of decrease, after 
pre-contraction with Phe. Acquisitions were made using LabChart 7 Pro 
v7.3.1 (ADInstruments, New Zealand). 
 
 
13. Statistical analysis 
Statistical analysis was performed using Graph Pad Prism software 
(version 5.0, Graph Pad software, USA). One-way ANOVA test was used for 
comparison among groups and two-way repeated-measures ANOVA test was 
used to performed analysis for repeated measures for the same animal. 
Single comparisons were assessed by an unpaired Student t test. Group data 
are presented as means ± SEM. Results were considered significantly 
different when p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part 4 
Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Science, in the very act of solving problems, creates more of them.” 
Abraham Flexner 
 
 
 
55 
 
1. Characterization of the animal model 
 
1.1. Morphometric data 
 Morphometric parameters were normalized to TL and are presented in 
Table 3. Body weight is significantly higher in ZSF1Ob when comparing 
ZSF1Ln and WKY and both ZSF1 groups are heavier than WKY. Regarding 
cardiac hypertrophy, ZSF1Ob and ZSF1Ln present increased LV weight/TL 
(Table 3), further confirmed histologically by their larger cardiomyocytes 
diameter (Figure 5) and echocardiographically by an augmented LV mass 
(Table 4). ZSF1Ob presented several organs that were significantly heavier 
than ZSF1Ln and WKY, such as perigonadal and perirenal fat, as expected in 
an obese model, and lung/TL, consistently with lung congestion. 
Gastrocnemius muscle weight normalized to TL was lower in ZSF1Ob when 
compared to ZSF1Ln, revealing cachexia (Table 3). 
Table 3. Morphological data from WKY (n=17), ZSF1Ln (n=14) and ZSF1Ob (n=18) 
animals. LV, left ventricle; RV, right ventricle; TL, tibial length. The values are 
represented as means ± S.E.M. p<0.05: * vs WKY, † vs ZSF1Ln. 
Morphometric parameters WKY ZSF1Ln ZSF1Ob 
Weight (g) 358.93±5.9 434.32±8.5* 606.13±6.6*† 
TL (mm) 39.75±0,8 43.10±1,0* 40.68±0.4† 
Heart weight/TL (mg.mm
-1
) 32.52±1.1 34.08±1.1 40.25±0.9*† 
RV weight/TL (mg.mm
-1
) 3.08±0.3 2.38±0.3 4.57±0.5† 
LV weight/TL (mg.mm
-1
) 8.56±0.8 9.44±0.8 10.81±0.5* 
Lung weight/TL (mg.mm
-1
) 41.59±2.2 44.08±2.3 63.73±4.0*† 
Spleen weight/TL (mg.mm
-1
) 15.18±1.0 16.69±1.0 21.58±1.1*† 
Pancreas weight/TL (mg.mm
-1
) 12.41±1.6 13.68±1.8 21.85±5.9 
Liver weight/TL (mg.mm
-1
) 275.32±9.1 324.15±11.8 936.36 ± 37.2*† 
Kidney weight/TL (mg.mm
-1
) 60.30±1.6 71.48±2.1 106.68±2.6*† 
Perirenal fat weight/TL (mg.mm
-1
) 62.32±4.3 52.64±5.7 372.30±10.3*† 
Perigonadal fat weight/TL (mg.mm
-1
) 57.82±3.1 58.28±3.5 137.19±6.4*† 
Gastrocnemius weight/TL (mg.mm
-1
) 54.31±1.0 62.17±1.7* 51.06±1.1† 
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Figure 5. Cardiomyocyte hypertrophy represented by its cross-sectional area (D). 
Representative images of hematoxylin-eosin stained section of LV from WKY (n=5, 
A), ZSF1Ln (n=5, B) and ZSF1Ob (n=5, C). The values are represented as means ± 
S.E.M. p<0.05: * vs WKY, † vs ZSF1Ln. 
 
1.2. Cardiac functional and structural changes 
Echocardiographic evaluation showed that ZSF1 groups presented 
preserved systolic function, as observed by similar cardiac index (CI), ejection 
fraction (EF) and end-diastolic volume index (EDVI) values. Global cardiac 
performance, assessed by the Tei index was similar between groups (Table 
4).  
In contrast with systolic parameters, significant disturbances in diastolic 
function were observed in ZSF1Ob animals compared to ZSF1Ln and WKY 
groups, namely, an increase in the maximum velocity of early diastolic 
D  
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transmitral flow to maximum velocity of myocardial displacement ratio at the 
lateral mitral annulus also in early diastole (E/E’) and a decrease in early and 
late LV filling velocities ratio (E/A). In addition, an increased left atrium area 
(LAA) was observed in ZSF1Ob (Table 4).  
 
 
Table 4. Echocardiographic evaluation of WKY (n=7), ZSF1Ln (n=9) and ZSF1Ob 
(n=15) animals at 18th week. CI, cardiac index; EF, ejection fraction; MPI, myocardial 
performance index  – Tei index; FS, fractional shortening; CO, cardiac output; LV, left 
ventricle; S’, mitral annular systolic velocity; SV, stroke volume; BSA, body surface 
area; ESVI, end-systolic volume index; ESDVI, end-diastolic volume index; E/E’, ratio 
of mitral velocity to early diastolic velocity of the mitral annulus; E/A, early and late 
LV filling velocities ratio; LAA, left atrium area; HR, Heart rate. The values are 
represented as means ± S.E.M. p<0.05: * vs WKY, † vs ZSF1Ln. 
 
Echocardiographic 
parameters 
WKY ZSF1Ln ZSF1Ob 
CI (mL.min-1.cm-2) 215.28 ± 21.20 193.49 ± 15.53 242.50 ± 12.89 
EF (%) 72.82 ± 3.28 74.30 ± 2.46 75.72 ± 1.19  
MPI (Tei index) 0.77 ± 0.04 0.74 ± 0.06 0.71 ± 0.03 
FS (%) 37.39 ± 2.66 38.61 ± 2.00 40.00 ± 1.03  
CO (L.min-1) 95.10 ± 10.45 95.36 ± 7.43 152.87 ± 8.70*† 
LVmass MM (mg) 0.57 ± 0.08 0.76 ± 0.10 0.92 ± 0.06* 
S' (mm.s-1) 0.03 ± 0.003 0.05 ± 0.01 0.05 ± 0.004 
SV (mL) 0.33 ± 0.04 0.29 ± 0.02 0.49 ± 0.03*† 
BSA (cm2) 439.83 ± 8.21 493.27 ± 6.27 628.19 ± 3.94*† 
ESV I (mL/cm-2) 0.47 ± 0.06 0.50 ± 0.07 0.50 ± 0.04 
EDV I (mL/cm-2) 1.75 ± 0.11 1.89 ± 0.11 2.10 ± 1.11 
E/E' 12.62 ± 0.62 12.06 ± 0.45 16.34 ± 0.43*† 
E/A 1.80 ± 0.11 1.57 ± 0.10 1.22 ± 0.05*† 
LAA (mm2) 0.21 ± 0.02 0.25 ± 0.01 0.36 ± 0.01*† 
HR (bpm) 290.53 ± 14.25 329.33 ± 11.16 318.91 ± 10.37 
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2. Aorta characteristics and vascular function  
 
Regarding structural changes, abdominal aorta from WKY and from 
both ZSF1 groups was analyzed and the diameter and thickness measured. 
Aortas from ZSF1Ob animals were clearly bigger (Figure 6A) and the 
diameter was significantly higher in both ZSF1 groups (Figure 6B). Regarding 
aortic thickness, ZSF1Ob aortas showed a tendency to be thicker relatively to 
the other two groups (Figure 6C). Interestingly, AGEs deposition was higher in 
vessels from WKY, meaning that AGEs were not responsible for vessels 
stiffening (Figure 6 D, E & F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 
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Figure 6. Descending aorta characteristics of WKY (n=5), ZSF1Ln (n=5) and 
ZSF1Ob (n=5) animals. A) Representative images of aorta morphology; B) Aortic 
diameter and C) Aortic thickness; D) 25-50µm caliber vessels AGEs; E) 50-100µm 
caliber vessels AGEs; F) >100µm caliber vessels AGEs. The values are represented 
as means ± S.E.M. p<0.05: * vs WKY. 
 
 
In terms of function, after stretching the aortic rings, the passive 
tension (Figure 7A) and the strain stiffness index was higher in ZSF1Ob 
(1.45±0.28, p<0.05) than in ZSF1Ln and WKY (1.12±0.06 and 0.89±0.04, 
p<0.05, respectively).  
Aortic rings were exposed to increasing concentrations of Phe to 
evaluate the vascular reactivity and the developed maximum active tension 
was significantly higher in ZSF1Ob group compared to WKY and ZSF1Ln 
groups (Figure 7B). ZSF1Ob group also displayed impaired relaxation 
(42±2%, p<0.05) comparing to ZSF1Ln and WKY (56±6% and 84±3%, 
D - 25-50µm caliber vessels E - 50-100µm caliber vessels 
F - >100µm caliber vessels 
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p<0.05, respectively) after the incubation with increasing concentrations of 
Ach (Figure 7C). 
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Figure 7. Vascular function of aortic rings from WKY (n=5), ZSF1Ln (n=5) and 
ZSF1Ob (n=5), animals. A) Strain-passive tension curve; B) Maximum active tension 
at phenylephrine (Phe) maximal concentration (10-5); C) Vascular relaxation to 
increasing doses of acetylcholine (Ach) pre-contracted with Phe. The values are 
means ± S.E.M. p<0.05: * vs WKY, † vs ZSF1Ln. 
 
 
3. Plasma levels of adipokines and inflammatory markers 
 
We performed a rat adipokine array kit to have an overview of the 
major plasma changes in ZSF1Ob versus ZSF1Ln using a small number of 
samples per group. Results are presented in table 5 and revealed that the 
expression of pro-inflammatory cytokines Il-1β and Il-6 displayed a small 
tendency to be lower in ZSF1Ob group when compared to ZSF1Ln. In 
contrast, the expression of ICAM1 showed a trend to increase in ZSF1Ob. No 
differences were found in relation to anti-inflammatory cytokines Il-11 and Il-
10 (Table 5). Interestingly, only levels of monocyte chemoattractant protein 1 
(MCP1), that actively recruits leukocytes into inflammatory sites, were 
significantly higher in ZSF1Ob. Lipocalin, a protein involved in the lipid 
transport which also has a role in inflammation, displayed a trend to have 
higher levels in the obese rats (Table 5). 
 
C 
WKY 
ZSF1Ln 
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Table 5. Plasma protein expression (% of change from the positive control) assessed 
by a profile array of ZSF1Ln (n=4) and ZSF1Ob (n=4) animals. Il-1β, interleukin-1β; 
Il-6, interleukin-6; TNFα, tumor necrosis factor α; ICAM1, intercellular adhesion 
molecule 1; Il-11, interleukin-11; Il-10, interleukin-10; MCP1, monocyte 
chemoattractant protein 1; RANTES, regulated on activation, normal T cell 
expressed and secreted. The values are represented as means ± S.E.M. p<0.05: † 
vs ZSF1Ln. 
Protein (%) ZSF1Ln ZSF1Ob 
Il-1β 6,1 4,0 
Il-6 2,9 1,8 
TNFα 2,5 2,8 
ICAM1 16,3 21,3 
Il-11 3,8 3,7 
Il-10 2,6 2,2 
MCP1 19,2 54,3 † 
RANTES 7,5 4,5 
Lipocalin 45,1 58,2 
 
 
 
We further confirmed some circulatory parameters by ELISA (Table 6), 
a more sensitive technique that revealed that plasma levels of leptin were 
significantly increased and there was a similar trend in FABP4 levels, 
consistently with metabolic syndrome (Table 6). In both ZSF1 groups, the 
vasodilator Ang 1-7 was significantly increase (p<0.05) to compensate for the 
increased ventricular overload and arterial stiffness present in these 
hypertensive groups (Table 6).  
Interestingly, plasma levels of pro-inflammatory cytokines such as Il-6 
and TNFα revealed a tendency to be higher in WKY group while, between 
ZSF1 groups, obese animals displayed slightly lower values than the lean 
ones, consistently with the array results (Table 6). 
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Table 6. Circulating plasma levels data from WKY (n=6), ZSF1Ln (n=9) and ZSF1Ob 
(n=8) groups. FABP4, fatty acid binding protein 4; Ang 1-7, angiotensin 1-7; Il-6, 
Interleukin-6;  TNFα, tumor necrosis factor α. The values are represented as means 
± S.E.M. p<0.05: * vs WKY, † vs ZSF1Ln. 
Protein WKY ZSF1Ln ZSF1Ob 
Leptin (pg.mL
-1
) 434.34 ± 136.67 405.77 ± 240.23 22150.15±10711.55*† 
FABP4 (ng.mL
-1
) 53.03 ± 18.53 83.27 ± 64.86 122.18 ± 81.34 
Angiotensin 1-7 (ng.mL
-1
) 1.84 ± 0.85 3.16 ± 1.04* 3.28 ± 0.46* 
Il-6 (pg.mL
-1
) 277.38 ± 218.29 176.67 ± 146.84 134.45 ± 68.92 
TNFα (pg.mL
-1
) 76.44 ± 42.15 71.57 ± 43.85 55.38 ± 15.44 
 
 
4. Markers of myocardial dysfunction 
 
 In addition, myocardial expression of some inflammatory-related and 
ROS-related genes and proteins was also measured by real-time PCR and 
western blotting and are shown in figures 8&9.  
When it comes to gene expression of endothelial function-related 
genes, E-selectin expression was higher in ZSF1 group (p<0.05), while in 
ICAM1, VCAM1, eNOS3 and endothelin 1 no significant differences were 
observed but only a trend towards their upregulation (Figure 8). 
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Figure 8. mRNA expression of WKY (n=5), ZSF1Ln (n=5) and ZSF1Ob (n=5) animals. 
A) ICAM1, intercellular adhesion molecule 1; B) VCAM1, vascular cell adhesion 
molecule 1; C) endothelin 1; D) eNOS, endothelial nitric oxide synthase; E) E-selectin. 
The values are represented as means ± S.E.M. p<0.05: * vs WKY. 
 
 
The expression of AGEs receptor (RAGEs) was not different between 
the ZSF1 groups (Figure 9A), but both results were significantly higher than 
WKY. AGES deposition, assessed by carboxymethyllysine (CML) expression, 
was similar between groups despite a trend towards an increase in ZSF1Ob 
(Figure 9B). Vasodilator-stimulated phosphoprotein (VASP) (Figure 9C) and 
eNOS protein (Figure 9D) expression had no differences.  
In ZSF1Ob rats, NOX2 expression, which promotes ROS production, 
increased in a significant way, compared with WKY and ZSF1Ln. Contrarily, 
NOX4 expression in ZSF1Ob, with protective properties against ROS, was 
significantly lower than the other groups (Figure 9E&F).  
E 
C D 
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Figure 9. Protein expression of WKY (n=6), ZSF1Ln (n=6) and ZSF1Ob (n=5) 
animals assessed by western blotting. A) RAGE, receptor of AGEs; B) CML, 
carboxymethyllysine; C) VASP, vasodilator-stimulated phosphoprotein; D) eNOS, 
endothelial nitric oxide synthase; E) NOX 2, NADPH oxidase 2; F) NOX 4, NADPH 
oxidase 4. The values are represented as means ± S.E.M. p<0.05: * vs WKY, † vs 
ZSF1Ln. 
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5. Flow cytometry analysis 
 
Representative scatter plots of flow cytometry analysis is depicted in 
figures 10A&B. Flow cytometry analysis revealed similar levels of CD31, a 
marker of endothelial cells, between ZSF1Ln and ZSF1Ob groups (Figure 
10C). Differently, ZSF1Ob LV samples display a significantly higher number of 
CD45 positive cells (Figure 10D), a marker of inflammation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Flow cytometry analysis. (A) Example of a representative plot of CD31 
versus CD45 expression from a ZSF1Ln animal. (B) Example of a representative plot 
of CD31 versus CD45 expression from a ZSF1Ob animal. (C) Expression of CD31+ 
cells in ZSF1Ln (n=3) and ZSF1Ob (n=5). (D) Expression of CD45+ cells in in 
ZSF1Ln (n=3) and ZSF1Ob (n=5). The values are represented as means ± S.E.M. 
p<0.05: † vs ZSF1Ln. 
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Discussion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“The important thing in science is not so much to obtain new facts as to discover new 
ways of thinking about them.” 
William Lawrence Bragg 
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The present study explored a previously described animal model of 
HFpEF, the ZSF1 obese rat, aiming to identify the pathophysiologic 
mechanisms underlying diastolic dysfunction progression. We have shown 
that the highly prevalent comorbidities associated to HFpEF trigger 
inflammation, oxidative stress and endothelial dysfunction in this animal 
model. 
 
1. Metabolic risk-related HFpEF model 
In this study we used the ZSF1 animal model and demonstrated that 
ZSF1Ob develops HFpEF at their 20th week of age. Compared to ZSF1Ln or 
WKY rats, ZSF1Ob showed many features of high metabolic risk such as 
visceral obesity evident from elevated perirenal and perigonadal fat, insulin 
resistance, hyperglycemia and physical inactivity evident from striated muscle 
wasting. ZSF1Ob rats present two different mutations for leptin receptor gene 
and as a compensatory response, leptin levels significantly increase. Lipocalin 
and FABP4 levels are also elevated in ZSF1Ob group, showing that in these 
rats adipose tissue is already dysfunctional and secreting a different pattern of 
adipokines. 
Comparing with WKY group, ZSF1Ln presented hypertension and 
consequent LV hypertrophy both at the organ and cellular level, which was 
further aggravated in ZSF1Ob rats. This hypertrophic response represents an 
attempt to normalize increased ventricular wall stress imposed by systemic 
arterial hypertension. Indeed, hypertrophy parallels the cardiac remodeling 
associated to HFpEF, namely in terms of ventricular size, geometry, shape 
and composition. Besides obesity, ZSF1Ob animals also developed 
hyperglycemia, oral glucose intolerance, insulin resistance, glycosuria and 
DM, all features that trigger diastolic dysfunction progression towards HFpEF 
[57]. Indeed, this represents an interesting aspect of ZSF1 as we were able to 
demonstrate that overload imposed by hypertension, as in ZSF1Ln, is not 
enough to induce diastolic dysfunction. Instead, only the concomitant 
presence of other significant comorbidities, as in ZSF1Ob, prompted HFpEF. 
Several studies have supported this finding by showing the severity of cardiac 
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and vascular injuries imposed by hypertension in obese or diabetic patients 
when compared with hypertension per se [66-69].  
The HFpEF presentation observed in this metabolic risk model also 
shares features with clinical presentation of this syndrome. Systolic function, 
evaluated by CI and EF, was preserved in all groups. Regarding diastolic 
function, the ZSF1Ob rats presented significant diastolic abnormalities as 
demonstrated by echocardiography evaluation, mainly and increased 
myocardial stiffness that compromises a proper ventricular filling. Previous 
studies from our groups showed that the relaxation time constant  is 
prolonged in ZSF1Ob, denoting also impaired relaxation [57]. Additionally, the 
obese group displayed dilated left atrium, lung congestion and increased 
arterial elastance, contributing to a worse ventricle-vascular coupling, a well 
establish cause of HFpEF [70]. All these results support the idea of ZSF1Ob 
as a good animal model of HFpEF. 
 The current animal model differs from previous experimental HFpEF 
models, which largely overlooked metabolic risk as they were carried out in 
old, hypertensive dogs [71, 72]  or in Dahl salt sensitive hypertensive rats [73].  
ZSF1Ob however closely resembles clinical HFpEF where metabolic risk is 
highly prevalent as evident from numerous HFpEF registries or large outcome 
trials [74-76]. HFpEF is a complex disorder that alters cardiac structure and 
function. Comorbidities commonly adjacent to this pathology, such as obesity, 
hypertension and diabetes mellitus, are associated with endothelial 
dysfunction [11, 51]. As a result, patients with HFpEF have an impaired NO 
response, elevated levels of vasoconstrictors and increased expression of 
adhesion molecules. Endothelium acquires a chronic inflammatory and pro-
thrombotic state where vasodilatation is compromised [32, 36]. Therefore, 
endothelial dysfunction may be a critical early target for the prevention of 
HFpEF, since that treatment options are still limited.  
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2. Endothelial dysfunction and oxidative stress 
Supplementary data related to vascular function demonstrate that 
ZSF1Ob animal’s aortas are less reactive. Furthermore, ZSF1Ob aortas are 
the largest and the thickest. In this group, besides the high passive tension, 
which indicates vascular stiffness, we also observed impairment of relaxation 
after incubation with a vasodilator substance. Altogether these data suggest 
endothelial dysfunction. Our results are in agreement with previous studies 
showing precisely that aortic rings in obese rats had a vasoconstrictive 
response [77]. Interestingly, Ang 1-7 circulating levels are increased in an 
attempt to compensate for the increase stiffness of ZSF1Ob arteries.  
Many HFpEF-associated comorbidities are known to induce cardiac 
and systemic ROS production, which further contributes to oxidative stress 
[78].  In our study the expression of NADPH oxidases, NOX4 and NOX2, with 
opposite functions, was in agreement with other studies where NOX 2 
upregulation in cardiac tissue was observed [79]. In ZSF1Ob, NOX2 
upregulation versus NOX4 downregulation clearly imbalances ROS 
production/protective mechanisms, promoting an oxidative stress 
environment. 
It is well known that DM-induced oxidative stress contributes to the 
formation of AGEs in cardiomyocytes [80]. Both ZSF1 groups demonstrated 
significantly higher levels of RAGEs and a small tendency to increase CML in 
ZSF1Ob. Others studies found similar results of RAGE levels in diabetic 
hearts [81]. These results were not confirmed by immunohistochemistry 
analysis of myocardial tissue. Thus this important signaling pathway needs to 
be clarified in subsequent studies. 
Increased systemic inflammation is a hallmark of all the comorbidities 
associated to this animal model. Interestingly, ZSF1Ob showed a slight 
tendency to have lower levels of several inflammatory mediators. This 
phenomenon has recently been described as the obesity paradox. This theory 
believes that obesity can, under certain circumstances actually have a 
positive effect due to the capacity of lipoproteins to neutralize 
72 
 
lipopolysaccharide derived from intestinal bacterial translocation. The 
mortality of obese patients with HF is low. This theory has been described as 
“reverse epidemiology” [82, 83]. So, the obesity presented by ZSF1Ob 
animals could attenuate the inflammatory effect. Interestingly, WKY displayed 
the highest levels of the pro-inflammatory Il-6 and TNFα. A possible 
explanation for this finding is that, WKY being a genetic model of depression, 
have hyper-responses to stress and display depression-associated 
abnormalities, like inflammation [84]. In fact, and supporting our results, other 
studies have been reported similar inflammatory levels [85, 86]. Current 
studies are being carried out in laboratory to clarify this aspect.  
Regarding tissue inflammation, the increase expression of E-selectin 
and CD45 in ZSF1Ob animals denotes increased levels of inflammation 
specifically in endothelial cells. 
All the above evidences suggest that ZSF1 animals do not display 
pronounced systemic alterations but present cardiac-tissue and vascular 
inflammation. Comorbidities stimulated the expression of inflammatory 
markers in ZSF1Ob hearts, mainly in endothelium, leading to diastolic 
dysfunction. We can conclude that comorbidities-induced inflammation and 
oxidative stress seem to be the hallmark of diastolic dysfunction and 
progression towards HFpEF.  
 
 
 
 
 
 
 
 
 
 
 
Part 6  
Conclusion and future perspectives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Somewhere, something incredible is waiting to be known.”  
Carl Sagan 
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Unfortunately and despite all advances in medicine, HFpEF still 
remains with no available therapeutic options. Endothelial dysfunction, a state 
present in HFpEF, seems to be involved in its pathogenesis. An appropriate 
animal model as ZSF1Ob will certainly help to better understand this 
syndrome as well as to test new potential therapeutic targets.  
Our data clearly show that ZSF1Ob rat presents diastolic dysfunction 
and HFpEF. Furthermore, both morphometric and metabolic studies already 
perform in our laboratory confirm the metabolic syndrome state of this animal 
model, corroborating its cardiometabolic risk, typically associated to HFpEF in 
the clinical scenario.  
 We fulfill our goal to evaluate endothelial dysfunction in the ZSF1Ob rat 
model. Our results evidently showed that ZSF1Ob aortas are predominantly 
under a rigid and vasoconstriction state. Thus, our data suggest that a 
dysfunctional endothelium induces an increased vascular stiffness and 
impaired relaxation, with obvious myocardial deleterious consequences. 
 We showed that cardiac endothelial cells from ZSF1Ob animals are 
under a state of endothelial inflammation, which suggests that comorbidities 
accumulated by these animals stimulate the expression of some important 
inflammatory markers, culminating in endothelial dysfunction. 
 There seems to be no doubt that endothelial dysfunction is related to 
HFpEF development. In this context, it is important to note that endothelium is 
no longer viewed as a physical barrier that basically separates blood from the 
vessel wall. In fact, over the years endothelial dysfunction has been 
associated with several diseases, including HFpEF. Important advances have 
been made to better understand this relationship but future studies will enable 
the development of new therapeutic targets with a possible cure. 
In the future we aim to complete our studies evaluating ROS 
systemically by measuring plasma levels of malondialdehyde (MDA) and 
urinary levels of 8-hydroxydeoxyguanosine (8-OHdG), both markers of 
oxidative DNA damage. We also want to detect ROS in cultured tissue with a 
dihydroethidium (DHE) oxidative fluorescent probe. Additionally we pretend to 
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measure NO levels in heart tissue as well as in vessels supernatant after 
functional studies.  
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